CNTMF:OTC-Cansortium Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.68

Change

0.00 (0.00)%

Market Cap

USD 0.08B

Volume

0.60M

Average Target Price

USD 1.20 (+76.47%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Cansortium Inc., through its subsidiaries, produces and sells medical cannabis in the United States. It operates cultivation, processing, and dispensary facilities in Florida and Texas; and a dispensary license in Pennsylvania. The company offers its products in the form of oral drops, capsules, suppositories, topicals, syringes, dried flowers, prerolls, and cartridges. It markets its products under the Fluent brand name. As of December 21, 2020, it operated 24 dispensaries. Cansortium Inc. was founded in 2015 and is headquartered in Miami, Florida.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-06 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BAYP Bayport International Holdings..

N/A

USD157.83B N/A N/A
MKKGY MERCK Kommanditgesellschaft au..

N/A

USD68.06B 29.97 17.34
MKGAF MERCK Kommanditgesellschaft au..

N/A

USD66.96B 29.67 17.34
TKPHF Takeda Pharmaceutical Company ..

N/A

USD55.48B 21.20 0.10
ESALY Eisai Co., Ltd

N/A

USD19.42B 32.44 0.13
ESALF Eisai Co., Ltd

N/A

USD19.37B 34.36 0.13
SGIOY Shionogi & Co., Ltd

N/A

USD15.67B 1.92 0.07
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD15.67B 26.11 3.30
SGIOF Shionogi & Co., Ltd

N/A

USD15.58B 15.44 0.07
TEVJF Teva Pharmaceutical Industries..

N/A

USD13.22B 900.00 16.02

ETFs Containing CNTMF

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -11.69% 11% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -11.69% 11% F 15% F
Trailing 12 Months  
Capital Gain 195.27% 70% C- 80% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 195.27% 70% C- 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -9.79% 36% F 19% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -9.79% 35% F 17% F
Risk Return Profile  
Volatility (Standard Deviation) 51.66% 63% D 42% F
Risk Adjusted Return -18.94% 33% F 27% F
Market Capitalization 0.08B 74% C 51% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.99 58% F 47% F
Price / Cash Flow Ratio -3.69 58% F 71% C-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -65.64% 43% F 16% F
Return on Invested Capital -33.80% 36% F 15% F
Return on Assets -0.32% 73% C 50% F
Debt to Equity Ratio 65.60% 15% F 28% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta -0.77 89% B+ 91% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector